STORM Therapeutics Limited
Entity

  • STORM Therapeutics Limited

    Created in 2015


  • Trend leader (A+)
    Existing signals make this entity one of the most dynamic startups

  • Social networks

    9,614

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    Cambridge CB22 3FH, UK

    Cambridge

    United Kingdom

  • Employees

    Scale: 11-50

    Estimated: 16

  • Engaged catalyst

    1
    0 0

  • Added in Motherbase

    3 months, 3 weeks ago
Description
  • Value proposition

    Harnessing the power of RNA modification

    STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets.

    STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases.

    The pipeline is exemplified by STORM’s METTL3 inhibitor (STC-15) for which an IND has been filed with the FDA to support initiation of a Phase I clinical trial in cancer patients in 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional candidates are planned for advancement into IND-track activities in 2023.

    STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.


    RNA modifications, mass spectrometry, drug discovery, oncology, biotech, and epigenetics

  • Home | Harnessing the power of RNA epigenetics | Cambridge, UK | STORM Therapeutics

    STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on developing small molecule inhibitors of RNA-modifying enzymes for the treatment of cancer.

    • https://www.stormtherapeutics.com/
Catalyst interactions
Catalyst Type Tweets Articles
IP Group plc
IP Group plc
Financial Services (Auto)
IP Group plc
Financial Services (Auto) 		Other

3 Feb 2025


Social network dynamics
Similar entities
BETA
Last news
Show all articles